Elite Wealth Management Inc. Purchases 2,230 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Elite Wealth Management Inc. grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,294 shares of the medical equipment provider’s stock after purchasing an additional 2,230 shares during the quarter. Intuitive Surgical comprises approximately 0.3% of Elite Wealth Management Inc.’s holdings, making the stock its 9th largest holding. Elite Wealth Management Inc.’s holdings in Intuitive Surgical were worth $9,695,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Provence Wealth Management Group acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at $276,000. Portside Wealth Group LLC lifted its position in Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after acquiring an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC bought a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $230,000. Finally, Blair William & Co. IL increased its holdings in shares of Intuitive Surgical by 3.1% during the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after purchasing an additional 11,400 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.6 %

Shares of NASDAQ:ISRG traded down $2.51 during trading on Thursday, reaching $398.39. The stock had a trading volume of 1,189,375 shares, compared to its average volume of 1,541,404. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $408.43. The company has a market capitalization of $141.31 billion, a P/E ratio of 71.91, a PEG ratio of 5.19 and a beta of 1.39. The firm’s 50-day simple moving average is $386.00 and its 200 day simple moving average is $360.92.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same period last year, the business earned $1.00 EPS. Equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Mizuho lifted their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. BTIG Research upped their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Robert W. Baird reduced their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Finally, Barclays boosted their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $387.22, for a total value of $67,763.50. Following the completion of the sale, the senior vice president now directly owns 533 shares in the company, valued at approximately $206,388.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $387.22, for a total transaction of $67,763.50. Following the sale, the senior vice president now owns 533 shares of the company’s stock, valued at $206,388.26. The disclosure for this sale can be found here. Insiders sold 148,290 shares of company stock worth $57,207,154 in the last three months. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.